v3.26.1
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 71 Months Ended
Feb. 28, 2026
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Mar. 31, 2032
May 31, 2026
Inventory Step-Up       $ 1,000 $ 2,349      
Intangible Asset, Finite-Lived, after Accumulated Amortization       45,678   $ 30,878    
Payments to Acquire Intangible Assets       15,000 (0)      
Intangible Asset, Finite-Lived, Amortization Expense       2,473 $ 2,002      
Impairment, Long-Lived Asset, Held-for-Use   $ 0 $ 0          
Finance Lease, Liability       0   $ 0    
Percentage for Valuation Reserve Against Deferred Tax Assets   100.00%       100.00%    
Hemangeol [Member]                
Intangible Asset, Finite-Lived, after Accumulated Amortization $ 12,969     $ 12,537        
Intangible Asset, Finite-Lived, Useful Life (Year) 10 years     10 years        
IMPAVIDO [Member]                
Intangible Asset, Finite-Lived, after Accumulated Amortization       $ 3,265       $ 3,304
Intangible Asset, Finite-Lived, Useful Life (Year)       10 years       10 years
Knight Therapeutics [Member] | IMPAVIDO [Member] | Forecast [Member]                
Payments to Acquire Intangible Assets             $ 4,250  
Computer Equipment [Member]                
Property, Plant and Equipment, Useful Life (Year)       3 years        
Furniture and Fixtures [Member]                
Property, Plant and Equipment, Useful Life (Year)       5 years        
Hemangeol [Member] | Pierre Fabre [Member]                
Payments to Acquire Marketing Rights $ 14,000              
Inventory Step-Up 1,131              
Payments to Acquire Marketing Rights, Acquisition Costs $ 100              
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | AnovoRx [Member]                
Concentration Risk, Percentage       90.40% 92.00%      
Customer Concentration Risk [Member] | Accounts Receivable [Member] | AnovoRx [Member]                
Concentration Risk, Percentage       88.10%   88.40%